{
  "docId": "019de072-75de-708e-aad9-55788df6c953",
  "docSlug": "5188528054c3088b6a98b04815eb3ce3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 40,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes detailed trial design diagrams for EMERALD-3 and SAFFRON studies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-75de-708e-aad9-55788df6c953/16",
  "deckHref": "/decks/019de072-75de-708e-aad9-55788df6c953",
  "deckJsonHref": "/decks/019de072-75de-708e-aad9-55788df6c953.json",
  "deckAnchorHref": "/decks/019de072-75de-708e-aad9-55788df6c953#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "EMERALD-3 trial design",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b0a2aed-f4ac-451a-bcef-9c2e14f013ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "SAFFRON trial design",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fcee7651-63b1-4dc3-a00a-25ffe3d119db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "GI = gastrointestinal; HCC = hepatocellular carcinoma; CTLA-4 = cytotoxic T-lymphocyte associated protein 4; VEGF = vascular endothelial growth factor; n = number; TACE = transarterial chemoembolisation; STRIDE = single tremelimumab...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec242be1-7adc-495c-b488-996fa838907a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.04,
        "y": 0.24
      },
      "kind": "list",
      "text": "Imfinzi: EMERALD-3 Expanding in GI cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1195f275-ca57-4e8b-93ea-2224e99dfc3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.35,
        "y": 0.24
      },
      "kind": "list",
      "text": "Tagrisso: SAFFRON Overcoming resistance mechanisms",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4a5ce57-55a5-4ae8-a907-bf742b2c3d71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.3,
        "x": 0.67,
        "y": 0.24
      },
      "kind": "table",
      "text": "Key upcoming news flow",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "219f9eb5-ffa3-4152-abb8-48af56b939e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "New trials start for Imfinzi in liver cancer and Tagrisso + Orpathys in lung cancer",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0354aa3-098c-4207-a934-526cc2302906",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Oncology: Q1 2022 R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d76faeca-fd83-46e1-8c2a-3868b13eb6d1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "0ffabe49-69fb-4a38-9b46-7ff7e4d97e12",
      "evidence": "Key upcoming news flow section",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "9033f2c1-0a31-4be1-9e9e-1cfab54f34ea",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The slides showcase the company's achievements in Oncology, BioPharmaceuticals, and Rare Disease",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 16,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a11d4c4b-770f-4828-bf13-5681ad15110b",
      "evidence": "The slides preview pioneering science and highlight R&D achievements",
      "position": 1,
      "objective": "Explaining the company's scientific leadership",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}